Japan's biggest drugmaker is hunting for partnerships and deals — at the right price — as it seeks to build an identity beyond the pharmacy shelves of its home market.
While Takeda Pharmaceutical Co. still has scope for acquisitions, after its $4.66 billion purchase of U.S. biotech Ariad Pharmaceuticals Inc. in January, selling assets, limiting debt levels and preserving its credit ratings are also goals, Chief Executive Officer Christophe Weber said Thursday in an interview in London. The company already has about 180 research partnerships, and will form more of them to build its pipeline.
The problem with acquisitions is finding the right assets "at a price point that makes sense," he said.